Skip to main content
. Author manuscript; available in PMC: 2021 Mar 20.
Published in final edited form as: Aliment Pharmacol Ther. 2015 Jun 29;42(5):582–590. doi: 10.1111/apt.13292

Figure 2 |.

Figure 2 |

Receiver operating characteristic curves for PTX-2. (a) PTX-2 level had an AUROC of 0.77 (95% CI: 0.65–0.90) for the identification of patients with advanced fibrosis. (b) PTX-2 had an AUROC of 0.84 (95% CI: 0.71–0.97) for the identification of NAFLD compared with normal controls.